Bed Bugs May Have Been The First Urban Pest to Ever Plague Humans
Humans were letting the bed bugs bite long before beds existed, and while they do live on other species, we're the main reason this notorious parasite is still going strong.
In fact, bed bugs might have been the first pest to plague our cities – earlier than the black rat, for instance, which joined us in urban life about 15,000 years ago, and even the German cockroach, which only got the memo about 2,100 years ago.
Researchers think the blood-sucking pests – Cimex lectularius – first jumped from their bat hosts onto a passing human some 50,000 years ago, a move which would change the course of the insect species forever.
Human bed bugs, it turns out, have boomed since the Last Glacial Maximum about 20,000 years ago. But it's a different story for those populations that continued living on bats.
"Initially with both populations, we saw a general decline that is consistent with the Last Glacial Maximum; the bat-associated lineage never bounced back, and it is still decreasing in size," says entomologist Lindsay Miles, from Virginia Tech.
"The really exciting part is that the human-associated lineage did recover and their effective population increased."
The researchers were able to track this evolution because the human bed bugs have a much narrower genetic diversity, since only a few 'founders' probably came with us when we abandoned life in caves. But our move into cities around 12,000 years ago is what really kicked off the human bed bug boom.
This was only briefly interrupted when DDT was invented in the 1940s. Populations crashed, humans slept sweetly, and then five years later, the bed bugs were back.
Since then, bed bugs have travelled around the world with us, and even become resistant to our pesticides. For now, it seems, bed bugs are here to stay. It's been a long-term relationship, after all.
The research is published in Biology Letters.
Your Brain Wrinkles Are Way More Important Than We Ever Realized
Something Strange Happens to Your Eyes When You're Sexually Aroused
2-Year-Old Prodigy Joins 'High IQ' Club Mensa as Youngest Member Ever
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
20 minutes ago
- CNN
New tech reveals never-before-seen details in solar corona
A breakthrough in adaptive optics technology captured the clearest images to date of the sun's corona. The incredible resolution of the new images could provide new insights on some of the mysteries surrounding our star.
Yahoo
43 minutes ago
- Yahoo
Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)
HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be presented at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago, U.S. Details of the Poster Presentations Poster Number: 750-P Abstract Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) Poster Number: 847-P Abstract Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) About ASC30 ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044. About ASC47 ASC47 is an adipose-targeted, ultra-long-acting subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue. Topline data from its Phase Ib single subcutaneous injection studies in Australia in participants with elevated low-density lipoprotein cholesterol (LDL-C) (NCT06427590) have been released. The Phase I clinical trial of ASC47 in combination with semaglutide for the treatment of obesity (NCT06972992) is ongoing in the U.S., and the first participants were dosed in May 2025. About the American Diabetes Association (ADA) Established in 1940, the American Diabetes Association (ADA) is dedicated to preventing and curing diabetes and to improving the lives of all people affected by diabetes. It has grown into one of the foremost nonprofit organizations in diabetes advocacy around the world. Its annual Scientific Sessions set the agenda for clinical practice and research innovation. The 85th Scientific Sessions of ADA will be held in Chicago, U.S. from June 20 to 23, 2025. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange ( covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit Contact： Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) Ascletis Pharma Inc. PR and IR teams +86-181-0650-9129 (China) pr@ ir@ View original content: SOURCE Ascletis Pharma Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
Mars by 2026? The 4 key takeaways from Elon Musk's Starship update
SpaceX's billionaire founder Elon Musk says that despite Starship setbacks, the space company hasn't taken its eyes off the ball — and that ball is big, red, and roughly 140 million miles away. In a 42-minute video posted to X on Thursday evening, Musk laid out a plan to launch the mammoth spacecraft to Mars for the first time as early as next year. His ultimate vision has been to use a fleet of Starships to send 1 million humans to Mars by 2050. To be clear, he doesn't just want to visit the planet; he wants to establish a permanent, independent city there. The new timeline is hard to fathom, especially for those who watched another Starship prototype explode this week. Though the ship reached space during the test, it failed to achieve many of its goals. Musk has earned a reputation for wildly underestimating schedules — he once aimed to send an uncrewed ship to Mars by 2018 — but that didn't stop him from presenting yet another ambitious timeline. "If we have two planets, we keep going," he said. "We can be out there among the stars, making science fiction no longer fiction." Here are the key takeaways from Musk's latest Mars update: SEE ALSO: Listen to the eerie sounds of Mars recorded by a NASA rover Elon Musk gave a presentation called "The Road to Making Life Multiplanetary." Credit: SpaceX / X screenshot Musk is now targeting late 2026 for the first uncrewed Starship flight to Mars, taking advantage of an orbital alignment that would shorten the journey between planets. The ship would arrive seven to nine months later in 2027. Musk considers the odds of launching in that upcoming window to be about 50-50. If SpaceX misses it, the next opportunity wouldn't come for another two years. In order to head to Mars that soon, SpaceX first has to master how to refuel a Starship in low-Earth orbit, after it has already blasted off the planet — something that, by the way, has never been done before. Though the first flight won't carry people, SpaceX still intends to put some butts in seats. The "crew" will consist of humanoid Optimus robots, built by Musk's electric car company, Tesla. During his talk, Musk presented some renderings of the sci-fi robots, including one meant as an homage to the famous Lunch atop a Skyscraper photo, with Optimuses (Optimi?) sitting together on a steel beam. "That would be an epic picture to see Optimus walking around on the surface of Mars," he said. NASA's Mars Odyssey spacecraft looked at Arcadia, a region with ice, in 2001. Credit: NASA / JPL / Arizona State University SpaceX is looking at several potential areas on Mars where Starship could land, but the lead candidate so far is a region known as Arcadia, which also happens to be the name of one of Musk's children. It's one of the few regions where lots of shallow ice exists relatively near the Martian equator, according to NASA. SpaceX will be prioritizing a location that isn't close to the poles, has ice as a source for water, and isn't too mountainous for the rockets, Musk said. With each Mars alignment launch window, SpaceX wants to increase its cadence of flights. To do that, they'll need a lot more rockets and ships. Right now the SpaceX plant in Starbase, Texas — which residents just voted to make a city — can make a new Starship every two to three weeks, Musk said. The company will build two so-called "Giga Bay" facilities — one in Texas and another in Florida — to ramp that up to several per day. He envisions 1,000 to 2,000 ships heading to the Red Planet every couple of years, with the ability to catch and reuse boosters within hours. The goal is to send enough people, infrastructure, and supplies so that if for some reason cargo shipments from Earth stop coming, the Martian city won't die. "My guess is that's about a million tons, but it might be 10 million tons. I hope it's not 100 million tons," he said. "That'd be a lot."
